Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Immisch et al

Detalles Bibliográficos
Autores principales: Chheda, Zinal S, Mueller, Sabine, Hegde, Bindu, Yamamichi, Akane, Butterfield, Lisa H, Okada, Hideho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10032395/
https://www.ncbi.nlm.nih.gov/pubmed/36944450
http://dx.doi.org/10.1136/jitc-2022-006617
_version_ 1784910789479497728
author Chheda, Zinal S
Mueller, Sabine
Hegde, Bindu
Yamamichi, Akane
Butterfield, Lisa H
Okada, Hideho
author_facet Chheda, Zinal S
Mueller, Sabine
Hegde, Bindu
Yamamichi, Akane
Butterfield, Lisa H
Okada, Hideho
author_sort Chheda, Zinal S
collection PubMed
description
format Online
Article
Text
id pubmed-10032395
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-100323952023-03-23 Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Immisch et al Chheda, Zinal S Mueller, Sabine Hegde, Bindu Yamamichi, Akane Butterfield, Lisa H Okada, Hideho J Immunother Cancer Letter BMJ Publishing Group 2023-03-21 /pmc/articles/PMC10032395/ /pubmed/36944450 http://dx.doi.org/10.1136/jitc-2022-006617 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Letter
Chheda, Zinal S
Mueller, Sabine
Hegde, Bindu
Yamamichi, Akane
Butterfield, Lisa H
Okada, Hideho
Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Immisch et al
title Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Immisch et al
title_full Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Immisch et al
title_fullStr Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Immisch et al
title_full_unstemmed Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Immisch et al
title_short Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Immisch et al
title_sort correspondence on 'h3.3k27m mutation is not a suitable target for immunotherapy in hla-a2+ patients with diffuse midline glioma' by immisch et al
topic Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10032395/
https://www.ncbi.nlm.nih.gov/pubmed/36944450
http://dx.doi.org/10.1136/jitc-2022-006617
work_keys_str_mv AT chhedazinals correspondenceonh33k27mmutationisnotasuitabletargetforimmunotherapyinhlaa2patientswithdiffusemidlinegliomabyimmischetal
AT muellersabine correspondenceonh33k27mmutationisnotasuitabletargetforimmunotherapyinhlaa2patientswithdiffusemidlinegliomabyimmischetal
AT hegdebindu correspondenceonh33k27mmutationisnotasuitabletargetforimmunotherapyinhlaa2patientswithdiffusemidlinegliomabyimmischetal
AT yamamichiakane correspondenceonh33k27mmutationisnotasuitabletargetforimmunotherapyinhlaa2patientswithdiffusemidlinegliomabyimmischetal
AT butterfieldlisah correspondenceonh33k27mmutationisnotasuitabletargetforimmunotherapyinhlaa2patientswithdiffusemidlinegliomabyimmischetal
AT okadahideho correspondenceonh33k27mmutationisnotasuitabletargetforimmunotherapyinhlaa2patientswithdiffusemidlinegliomabyimmischetal

Ejemplares similares